Last reviewed · How we verify
GLPG0259
At a glance
| Generic name | GLPG0259 |
|---|---|
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects (PHASE1)
- First-in-Human Single Ascending and Multiple Dose of GLPG0259 (PHASE1)
- GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis (PHASE2)
- Oral Bioavailability of Two Solid Formulations of GLPG0259. (PHASE1)
- GLPG0259 Solid Formulation Bioavailability and Food Effect (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG0259 CI brief — competitive landscape report
- GLPG0259 updates RSS · CI watch RSS
- Galapagos NV portfolio CI